|Ask||36.97 x 500|
|Day's Range||35.09 - 35.21|
|52 Week Range||33.52 - 38.86|
|PE Ratio (TTM)||N/A|
|Expense Ratio (net)||0.63%|
MADRID, May 19, 2017 /PRNewswire/ -- PharmaMar (MCE: PHM) will present data obtained from various clinical studies for its activated transcription inhibitors, Yondelis ® and lurbinectedin, during the 53 ...
Some 20 years ago, a low rumbling of change began to build in the retail industry. Remember when Amazon, despite losing billions of dollars a year, started to eat the market-share lunch of bookstores? There was clear disruption going on, but really in a small material way back then. However, there were those who saw the future, and extrapolated that what Amazon was doing to bookstores would happen across retail. Many scoffed.
In the framework of the Annual Congress of the Association for Research in Vision and Ophthalmology 2017 (ARVO), being held from the 7-11 of May in Baltimore (USA), Sylentis, a pharmaceutical company from the PharmaMar Group (PHM), presents new preclinical and clinical developments with its molecule SYL1001 for the treatment of dry eye disease. This Congress will bring together more than 11,000 top eye and vision researchers and clinicians from around the world to explore cutting-edge basic and clinical science.